Search

... recruited from cardiology or diabetes clinics (using either Embletta ...

... or pregnancy-induced hypertension and diabetes, were not exclusion criteria. ...

... disease, metabolic diseases including diabetes, and mood disorders. At ...

... prevalence of co-morbidities (e.g. diabetes, hypertension) than no insomnia/OSA. ...

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-GLUCOSIDASE INHIBITORS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BIGUANIDES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking K-CHANNEL BLOCKERS TO ENHANCE INSULIN SECRETION FOR DIABETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking FIRST GENERATION SULFONYLUREAS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SECOND GENERATION SULFONYLUREAS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZOLIDINEDIONES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.